Personalized treatment for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks for markers in your blood to help doctors choose the most effective treatment, especially a drug called venetoclax. By understanding your leukemia at a very detailed level, they hope to improve outcomes for you and others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with acute myeloid leukemia (AML).
- You must be able to follow the study plan and provide informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a software tool that uses your genes and machine learning to find the best dose of venetoclax for you. It aims to improve treatment outcomes and reduce side effects for people with acute myeloid leukemia (AML).
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This study tests whether using a genetic profile of your leukemia plus a very sensitive test for leftover cancer cells can guide a more personalized treatment plan. The goal is to give you the most effective therapy while avoiding unnecessary side effects.
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.